U.S. markets closed
  • S&P Futures

    4,206.00
    -17.00 (-0.40%)
     
  • Dow Futures

    33,911.00
    -106.00 (-0.31%)
     
  • Nasdaq Futures

    13,894.75
    -86.50 (-0.62%)
     
  • Russell 2000 Futures

    2,299.10
    -11.00 (-0.48%)
     
  • Crude Oil

    71.58
    -0.57 (-0.79%)
     
  • Gold

    1,818.90
    -42.50 (-2.28%)
     
  • Silver

    27.23
    -0.59 (-2.11%)
     
  • EUR/USD

    1.1993
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.5690
    +0.0700 (+4.67%)
     
  • Vix

    18.15
    +1.13 (+6.64%)
     
  • GBP/USD

    1.3979
    -0.0007 (-0.05%)
     
  • USD/JPY

    110.7800
    +0.1670 (+0.15%)
     
  • BTC-USD

    38,548.82
    -1,571.29 (-3.92%)
     
  • CMC Crypto 200

    953.95
    -38.52 (-3.88%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,291.01
    0.00 (0.00%)
     

Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021, after the markets close. Aurinia’s management team will also host a conference call at 5:00 p.m. EDT to discuss the Company’s financial results and to provide a general business update.

The conference call and webcast is scheduled for May 6, 2021 at 5:00 p.m. ET. In order to participate in the conference call, please dial +1-888-506-0062 (toll-free U.S.) or +1-973-528-0011 (international); entry code: 662377. The audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will also be available on Aurinia’s website approximately two hours after the live call is completed.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005151/en/

Contacts

Investor Contact:
Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
gschulman@auriniapharma.com